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Background: As a key regulator in lipid mobilization, AZGP1 has been reported to play a 
significant role in various cancers. This study was carried out to investigate the role of AZGP1 in 
the development of esophageal squamous cell carcinoma (ESCC) patients in Northern China.
Materials and methods: Through the application of quantitative real-time polymerase chain 
reaction and immunohistochemical staining, AZGP1 expression in ESCC tissues from Northern 
China was examined.
Results: Decreased expression of AZGP1 was observed in ~60% ESCC patients. AZGP1 
downregulation was significantly associated with lymph node metastasis (P=0.035), advanced 
clinical stage (P=0.018), poor prognosis for 5-year disease-specific survival (DSS; P,0.001), 
local recurrence-free survival (LRFS; P=0.016), and metastasis-free survival (MeFS; P=0.014). 
In addition, Cox multivariate analysis revealed that AZGP1 downregulation remained to 
be an independent prognosticator for shorter DSS (P=0.001), LRFS (P=0.011), and MeFS 
(P=0.004).
Conclusion: AZGP1 might be a candidate tumor suppressor and a potential novel prognostic 
biomarker for ESCC patients in Northern China.
Keywords: AZGP1, ESCC, prognosis, Northern China
Introduction
With incidence varying greatly by geographic location and ethnicity,1,2 esophageal 
cancer (EC) is one of the leading causes of cancer death worldwide. Due to lifestyle, 
dietary habits, and multiple genetic alterations, Northern China has one of the high-
est rates of EC in the world. Accounting for .90% of EC, esophageal squamous cell 
carcinoma (ESCC) predominates in eastern countries, particularly in Northern China.3,4 
In spite of recent advances in diagnosis and therapeutic options, the prognosis is still 
poor with ~10%–41% average overall 5-year survival rate.5–8 Decreasing the mortality 
rate will require early diagnosis and effective treatment for ESCC patients. So far, 
genetic alterations have been widely investigated; however, reliable biomarkers for 
clinical diagnosis, prognosis, and therapeutic efficiency evaluation are still lacking. 
Therefore, identifying more effective biomarkers for early diagnosis and targeted 
therapies is of significant clinical value.
In order to identify more novel EC-related genes that might be potential biomark-
ers for diagnosis or therapeutic targets, cDNA microarray technology was adopted 
to simultaneously analyze the changes in the expression of thousands of genes. 
In our previous research, a number of discriminatively expressed genes have been 
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identified, such as CTTN, EMS1, AZGP1 HMGCS2, and 
SORBS29 through Affymetrix Human Genome U133 Plus 2.0 
GeneChip consisting of 47,000 transcripts, so as to compare 
gene expression profiles between tumor tissues and matched 
normal epithelia from 10 ESCC specimens. In this study, 
AZGP1 expression in primary ESCC and the correlation 
with clinical parameters were verified.
Materials and methods
statement of ethics
ESCC tissue samples used in this study were approved by the 
Committees for Ethical Review of Research involving Human 
Subjects at Zhengzhou University (Zhengzhou, People’s 
Republic of China). Written informed consent for the original 
human work producing tissue samples was obtained.
escc clinical samples
After surgical resection at Linzhou Cancer Hospital, Northern 
China, primary ESCC tumor tissues and their paired nontu-
mor tissues were immediately collected from the proximal 
resection margins. Some was quickly put into vials stored 
in liquid nitrogen, and other tumor tissues were routinely 
formalin-fixed and paraffin-embedded. The inclusion criteria 
were listed as follows: 1) histological evidence of ESCC, 
2) complete surgical resection (R0), 3) no perioperative 
chemotherapy and/or radiotherapy treatment, and 4) com-
plete follow-up for 60 months. TNM staging is based on the 
American Joint Committee on Cancer Guidelines.10
Quantitative real-time polymerase chain 
reaction (qrT-Pcr)
By adopting TRIzol (Invitrogen, Carlsbad, CA, USA), total 
RNA was extracted from frozen ESCC tissues. According 
to the manufacturer’ instructions, reverse transcription of 
total RNA (2 μg) was done by making use of Advantage 
RT-for-PCR Kit (Clontech). In order to detect the expres-
sion level of corresponding β-actin and AZGP1, qRT-PCR 
was performed with an SYBR Green PCR Kit (Applied 
Biosystems) and ABI 7900HT Fast Real-Time PCR System 
(Applied Biosystems). β-Actin served as an internal control 
for AZGP1. In Table 1, primers of AZGP1 and β-actin are 
listed. To validate them, we have tested PCR products in 
gels to confirm the accuracy and specificity of PCR amplifi-
cation (Figure S1). SDS2.3 software (Applied Biosystems) 
was used to analyze relative expression levels. Through the 
Ct method, the real-time value for each sample was aver-
aged and compared. ∆∆Ct (sample) = ∆Ct (sample) - ∆Ct 
(calibrator), ∆Ct (sample) = Ct (sample) of target gene - Ct 
(sample) of β-actin, ∆Ct (calibrator) = Ct (calibrator) of target 
gene - Ct (calibrator) of β-actin; calibrator was defined as 
pooled samples from 45 adjacent nontumor tissues.
escc tissue microarray (TMa) and 
immunohistochemical (ihc) staining
Containing 300 pairs of primary ESCC tissue samples and 
their corresponding nontumor tissues, TMAs were constructed 
as described previously.9 In short, tissue sections with a thick-
ness of 5 μm were cut from TMA blocks and mounted on 
microscope slides. By using the standard streptavidin–biotin–
peroxidase complex method, IHC staining was performed.9 
TMA slides were deparaffinized in xylene, rehydrated by a 
graded alcohol series, and incubated with 3% hydrogen perox-
ide. For antigen retrieval, TMA slides were boiled in 10 mM 
sodium citrate buffer (pH 6.0) for 15 minutes through a pres-
sure cooker. Blocked by 10% normal mouse serum at room 
temperature for 30 minutes, the slides were then incubated 
with primary anti-AZGP1 monoclonal antibody (Proteintech; 
1:200 dilution) at 4°C overnight, which has been confirmed 
by Western blot assay (Figure S2). At a concentration of 
1:75, the TMA section was incubated with biotinylated goat 
antimouse immunoglobulin at 37°C for 30 minutes. Through 
the application of ImmPress Universal Kit (Vector Labora-
tories, Burlingame, CA, USA), primary antibody staining 
was visualized with NovaRed (Vector Laboratories) as a 
substrate. In the next step, the sections were counterstained 
with hematoxylin, dehydrated, and mounted. As stated 
before, an immunoreactivity score system was applied.11 The 
percentage of AZGP1-positive cells was scored as 0, ,5% 
negative; 1, 5%–25% sporadic; 2, 25%–50% focal; and 3, 
.50% diffuse. In addition, the intensity of AZGP1-positive 
staining was scored as 0, negative; 1, weak; 2, moderate; 
and 3, strong. Both the percentage of positive cells and the 
intensity of cell staining were determined in a double-blinded 
manner. According to the following formula, the total score 
was determined: staining index = intensity × positive rate. In 
this study, staining index of not more than 4 was regarded 
as down expression and staining index of more than 4 was 
regarded as normal expression.
Table 1 Primer sequences used for quantitative polymerase chain 
reaction analyses
Gene Sequence Accession no
AZGP1 q-F 5′-aacgacagTaacgggTcTcac-3′ nM_001185.3
AZGP1 q-R 5′-TTggTTaTcTgggcTgcTgg-3′
β-Actin q-F 5′-caTgTacgTTgcTaTccaggc-3′ XM_006715764.1
β-Actin q-R 5′-cTccTTaaTgTcacgcacgaT-3′
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
14
5 
on
 0
4-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
87
aZgP1 expression in esophageal cancer
statistical analysis
SPSS standard version 16.0 was adopted to perform sta-
tistical analysis, and paired two-tailed t-test was used to 
compare AZGP1 expression in primary ESCC tumors and 
their paired nontumorous tissues. Through χ2 test or Fisher’s 
exact tests, the statistical significance of correlations between 
AZGP1 expression and clinicopathologic characteristics was 
assessed. The points for disease-specific survival (DSS), 
local recurrence-free survival (LRFS), and metastasis-free 
survival (MeFS) were calculated from the surgery date to 
the date that event developed. Survival curves were plot-
ted through Kaplan–Meier method, and statistical analysis 
was performed through log-rank test. And then, parameters 
demonstrating prognostic significance at the univariate test 
were enrolled into multivariate comparisons through the Cox 
proportional hazards model. P,0.05 was considered to be 
statistically significant.
Results
Frequent downregulation of aZgP1in 
escc
By using qRT-PCR, the mRNA expression of AZGP1 was 
compared between tumor and their paired nontumor tissues 
in 45 ESCC patients. When compared with their normal 
counterparts, the relative expression level of AZGP1 was 
significantly downregulated in tumor tissues (P,0.001; 
Figure 1). AZGP1 downregulation was detected in 29/45 
(64.4%) ESCC tumors compared with their normal coun-
terparts (defined as a 2-fold decrease of AZGP1 expression 
in tumors). Using a TMA, AZGP1 expression in protein 
level was further studied by IHC. Informative results were 
obtained from 215 pairs of ESCCs. Noninformative samples 
were not included in data analysis, including 57 cases of 
lost samples, 9 cases of unrepresentative samples, 13 cases 
of samples with too few tumor cells, and 6 cases of sam-
ples with inappropriate staining. As the staining index of 
AZGP1 was $4 in nontumor tissue, staining index of not 
less than 4 was then counted as normal AZGP1 expression. 
When staining index was ,4, AZGP1 downregulation was 
defined, which was detected in 118/215 (54.9%) ESCC 
tissues compared with their adjacent nontumor tissues 
(P,0.001; Figure 2), and the corresponding hematoxylin 
and eosin staining was visible in Figure S3. In both mRNA 
and protein level, a consistent result was detected in AZGP1 
expression.
correlation of aZgP1 downregulation 
with clinicopathologic characteristics
Next, the clinical association between AZGP1 protein 
expression and clinicopathologic characteristics of 
ESCC patients from Northern China were examined. The 
analysis results demonstrated that AZGP1 downregula-
tion was significantly associated with pathologic N status 
(P=0.035) and advanced clinical staging (P=0.018). More-
over, no correlation was observed between AZGP1 expres-
sion and patient’s age (P=0.067), gender (P=0.487), tumor 
location (P=0.173), tumor cell differentiation (P=0.721), 
pathologic T status (P=0.112), and general classification 
(P=0.899; Table 2).
Prognostic impact of aZgP1 expression 
in escc
The mean follow-up duration of these patients was 
27.4 months (ranging from 1 to 60 months). Kaplan–Meier 
analysis revealed that ESCC patients with AZGP1 downregu-
lation (median survival time of 18 months) had a shorter DSS 
Figure 1 Downregulation of aZgP1 in escc tumor tissues.
Notes: (A, B) Quantitative real-time polymerase chain reaction was used to compare aZgP1 expression between tumor and nontumor tissues in 45 esccs. The result 
was normalized by β-actin. each sample was analyzed in triplicate. ***P,0.01.
Abbreviation: escc, esophageal squamous cell carcinoma.
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Figure 2 representative of aZgP1 expression in two pairs of escc (below) and adjacent normal tissue (above) were detected by immunostaining with anti-aZgP1 
antibody (brown).
Notes: The slides were counterstained with hematoxylin. Original magnification: ×100 (left) and ×200 (right).
Abbreviation: escc, esophageal squamous cell carcinoma.
?????? ??????
???
???
???
?
???
??
Table 2 association of aZgP1 expression with clinicopathologic features of patients with esophageal squamous cell carcinoma 
(n=215)
Clinicopathologic  
features
n AZGP1 expression, n (%) χ2 P-value
Downregulation Normal expression
age (years) 3.367 0.067
#60 125 62 (49.6) 63 (50.4)
.60 90 56 (62.2) 34 (37.8)
gender 0.482 0.487
Male 123 65 (52.8) 58 (47.2)
Female 92 53 (57.6) 39 (42.4)
location 3.512 0.173
Upper 43 28 (65.1) 15 (34.9)
Middle 108 53 (49.1) 55 (50.9)
lower 64 37 (57.8) 27 (42.2)
Tumor cell differentiation 0.654 0.721
Well 31 15 (48.4) 16 (51.6)
Moderate 135 75 (55.6) 60 (44.4)
Poor 49 28 (57.1) 21 (42.9)
T category 5.992 0.112
T1 14 4 (28.6) 10 (71.4)
T2 43 23 (53.5) 20 (46.5)
T3 78 41 (52.6) 37 (47.4)
T4 80 50 (62.5) 30 (37.5)
n category 4.442 0.035*
n0 116 56 (48.3) 60 (51.7)
n1 99 62 (62.6) 37 (37.4)
TnM stage 8.080 0.018*
i 11 2 (18.2) 9 (81.8)
ii 119 63 (52.9) 56 (47.1)
iii 85 53 (62.4) 32 (37.6)
General classification 0.590 0.899
Medullary type 117 67 (57.3) 50 (42.7)
Ulcerative type 54 28 (51.9) 26 (48.1)
sclerotic type 21 11 (52.4) 10 (47.6)
Mushroom type 23 12 (52.2) 11 (47.8)
Notes: *Statistically significant. TNM staging is based on AJCC Guidelines.10
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than patients with normal AZGP1 expression (median survival 
time of 30 months, P,0.000; Figure 3A). Furthermore, no 
significant difference in DSS was observed in patients with 
TNM stage III (P=0.295) in a stratified survival analysis 
according to the TNM stage. However, AZGP1 expression 
could differentiate the prognosis of patients among those with 
TNM stage I–II (P,0.001; Figure 3B). Similarly, patients 
with AZGP1 downregulation had a shorter median LRFS 
(9 months vs 15 months, P=0.016; Figure 3C) and median 
MeFS (9.5 months vs 17 months, P=0.014; Figure 3D). 
In univariate analysis of these clinicopathologic parameters 
(Table 3), there were a number of risk factors that were sig-
nificantly associated with worse DSS, including pathologic 
T status (P,0.001), pathologic N status (P,0.001), and 
tumor cell differentiation (P=0.002). Through the applica-
tion of multivariate analysis (Table 4), advanced pathologic 
T status (P=0.001) and pathologic N status (P,0.001) 
were identified as independent risk factors for tumor local 
recurrence. Furthermore, pathologic T status (P=0.005) and 
pathologic N status (P,0.001) were independent factors 
for tumor metastasis prediction. But above all, downregu-
lated AZGP1 was significantly predictive for worse DSS 
(P,0.001), LRFS (P=0.026), and MeFS (P=0.018), as shown 
in Table 3 and Figure 2. In multivariate analysis, downregu-
lated AZGP1, pathologic T status, and tumor cell poor dif-
ferentiation were prognostically significant for inferior DSS 
(P=0.001, P,0.001, and P=0.005, respectively). Moreover, 
AZGP1 expression, pathologic T status, and pathologic 
N status were independent prognostic predictors for LRFS 
(P=0.011, P=0.040, and P=0.014, respectively), AZGP1 
expression and pathologic N status for MeFS (P=0.004 and 
P=0.009, respectively; Table 3).
Figure 3 survival curves plotted by employing Kaplan–Meier estimator.
Notes: (A) Kaplan–Meier plot with univariate analysis indicated that patients with low aZgP1 expression had a poor Dss (P,0.01) than those with normal aZgP1 
expression, log-rank test. (B) A stratified survival analysis according to the pathological stage revealed that AZGP1 expression discernibility on DSS was only pronounced in 
patients with advanced clinical stage (stage i–ii; P,0.001), log-rank test. (C, D) Kaplan–Meier plot with univariate analysis indicated that patients with low aZgP1 expression 
had a poorer local recurrence-free (P=0.016) and metastasis-free survival (P=0.014) than those with normal aZgP1 expression, log-rank test.
Abbreviation: DSS, disease-specific survival.
???
???
??? ?????????????????
???????????????
??????
???
???
???
? ?? ?? ??????????????????????
???
???
????
????
??
???
????
????
?
?????????????????
???????????????
?????????????????
? ?? ?? ??????????????????????
???
???
???
???
???
???
???
???
????
????
??
???
????
????
?
?????????????????
???????????????
???????
? ???? ????????????????????????
???
???
???
???
???
???
???
?????
???
???
????
???
???
????
????
?
?????????????????
???????????????
???????
? ???? ????????????????????????
???
???
???
???
???
???
???
????
????
????
???
????
????
?
? ?
? ?
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
14
5 
on
 0
4-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
90
Tang et al
Table 3 Univariate log-rank analysis for clinicopathologic features and aZgP1 expression
Parameter Case DSS LRFS MeFS
No of events P-value No of events P-value No of events P-value
age (years) 0.128 0.052 0.953
#60 125 100 31 53
.60 90 75 22 40
gender 0.816 0.790 0.119
Male 123 105 29 53
Female 92 70 24 40
location 0.364 0.582 0.573
Upper 43 35 12 21
Middle 108 83 23 44
lower 64 57 18 28
Differentiation 0.002* 0.080 0.244
Well 31 21 5 9
Moderate 135 111 35 60
Poor 49 43 13 24
T category 0.000* 0.001* 0.005*
T1 14 9 2 1
T2 43 31 5 7
T3 78 63 14 35
T4 80 72 32 50
n category 0.000* 0.000* 0.000*
n0 116 88 19 38
n1 99 87 34 55
aZgP1 expression 0.000* 0.026* 0.018*
Downregulation 118 101 33 55
normal expression 97 74 20 38
General classification 0.870 0.140 0.743
Medullary type 117 102 25 56
Ulcerative type 54 41 15 20
sclerotic type 21 17 6 7
Mushroom type 23 15 7 10
Notes: *Statistically significant. TNM staging is based on AJCC Guidelines.10
Abbreviations: Dss, disease-special survival; lrFs, local recurrence-free survival; MeFs, metastasis-free survival.
Table 4 Multivariate analysis
DSS LRFS MeFS
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
T category 1.468 1.200–1.796 0.000* 1.593 1.021–2.485 0.040* 1.031 0.657–1.562 0.953
n category 1.396 0.981–1.987 0.064 2.660 1.215–5.824 0.014* 2.483 1.259–4.896 0.009*
aZgP1 expression 0.607 0.447–0.825 0.001* 0.464 0.257–0.839 0.011* 0.519 0.333–0.808 0.004*
Differentiation 1.420 1.111–1.814 0.005* – – – – – –
Notes: *Statistically significant. TNM staging is based on AJCC Guidelines.10
Abbreviations: CI, confidence interval; DSS, disease-special survival; HR, hazard ratio; LRFS, local recurrence-free survival; MeFS, metastasis-free survival.
Discussion
Recently, AZGP1 has been highlighted to play a crucial role 
in carcinogenesis in human cancers.12–15 To our knowledge, 
this is the first study to explore the relationship between 
AZGP1 gene expression and human ESCC occurrence and 
development. In this study, it was shown that when com-
pared with their paired normal control, both mRNA and 
protein expression of AZGP1 was significantly downregu-
lated in ESCC tissues. Moreover, AZGP1 downregulation 
was notably more prevalent in patients with lymph node 
metastasis, advanced clinical staging, shorter DSS, LRFS, 
and worse MeFS. These results might suggest AZGP1 as a 
novel prognostic biomarker for ESCC.
Assigned to chromosome 7q22.1, AZGP1 is a soluble 
41 kDa secreted glycoprotein, which was identified from 
human plasma, and its chemical structure and properties 
were explored by Burgi and Schmid.16 As an adipokine in 
human adipocytes, cancer cell, AZGP1 plays a key role in 
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lipid mobilization.17 There is evidence to show that due to 
the high level of amino acid sequence homology with a 
tumor-derived lipid-mobilizing factor, AZGP1 is associated 
with cancer cachexia by stimulating lipid degradation in 
adipocytes.18,19 In recent studies, AZGP1 was reported to be 
overexpressed in some tumors, but lost or reduced expres-
sion in other tumors.20,21 Although the exact mechanism 
remains unclear, AZGP1 expression has been demonstrated 
to be regulated by the acetylation status of histone, which 
regulates gene activity by means of changing chromatin 
conformation.22 It is shown that AZGP1 is downregulated in 
lung adenocarcinoma through inhibiting histone acetylation.21 
On the contrary, it is histone deacetylation that results in lost 
expression of AZGP1 in pancreatic adenocarcinoma.23 In this 
study, the rates of AZGP1 downregulation were 64.4% and 
54.9% in mRNA and protein level, respectively. Therefore, 
whether histone deacetylation contributes to AZGP1 down 
expression in ESCC requires further investigation.
It was indicated that AZGP1 downregulation was asso-
ciated with tumor cells poor differentiation in a majority 
of popular tumors, such as breast cancer, prostate cancer, 
oral squamous cell carcinomas, pancreatic cancer, cervi-
cal cancer, and gastric cancer.14,15,21–24 Because of its high 
structural homology to the major histocompatibility complex 
class I family, AZGP1 plays a antitumor role by participating 
the immune response.12 By downregulating mammalian 
target of rapamycin signaling pathway downstream and 
inhibiting cdc2 that could regulate G2/M transition, AZGP1 
overexpression impaired the proliferation and migration 
potential.25 The relationship between AZGP1 expression 
and cancer patients’ clinical stages is incomprehensible. 
In bladder cancer, AZGP1 expression was increased in a 
stage-dependent manner;13 however, its expression was 
inversely related to tumor stage in prostate cancer and gastric 
cancer.24,26 It was reported that low AZGP1 expression was 
associated with advanced T stage in gastric cancer.24 In this 
study, the percentage of AZGP1 protein downregulation 
increased as tumor cell differentiation degree decreased. 
Nevertheless, there was no statistical significance between 
AZGP1 protein downregulation and tumor cell differentia-
tion. However, AZGP1 protein downregulation was notably 
more correlated with lymph node metastasis and advanced 
clinical stage. Besides, it was proven that lower AZGP1 
level could induce TGF-β mediated epithelial–mesenchymal 
transition, while AZGP1 overexpression could maintain the 
epithelial phenotype in pancreatic cancer.21 These findings 
might explain why AZGP1 downregulation promotes metas-
tasis. In addition, there was no correlation between AZGP1 
expression and tumor location, pathologic T status, and 
general classification. Our findings suggested that AZGP1 
down expression might promote ESCC progression.
In the past, a number of studies confirmed that AZGP1 
downregulation was relevant to poor prognosis, which has 
been identified as a predictor of prognosis in various malig-
nant tumors.24,27–30 In lung adenocarcinoma and prostate 
cancer, patients with low levels of AZGP1 were reported to 
be associated with worse survival than those with high levels 
of AZGP1.26,31 Utilizing numerous prostate cancer cases, 
Jung et al32 demonstrated the superiority of AZGP1 over 
other prognosis factors in predicting biochemical recurrence, 
such as hCAP-D3, mucin 1, vimentin, E-cadherin, and ERG. 
Another research showed that in the analysis of patients with 
early-stage breast cancer, the presence of AZGP1 protein was 
related to poor DSS and overall survival time.33 By making 
use of Kaplan–Meier survival analysis, ESCC patients with 
AZGP1 down expression had a significantly shorter DSS 
than those with normal expression in this study. Univari-
ate analyses showed that decreased AZGP1 expression in 
ESCC tissues, tumor cells differentiation, and pT and pN 
categories were significantly associated with 5-year sur-
vival rate. Multivariate analysis demonstrated that AZGP1 
expression, tumor cells differentiation, and pT category were 
independent risk factors for ESCC patients’ DSS. Further-
more, normal AZGP1 expression was significantly related 
to longer clinical recurrence period and distant metastasis. 
Cox regression analysis indicated that AZGP1 might be 
one of the factors affecting ESCC patients’ recurrence and 
metastasis. These observations suggested that after surgical 
resection, AZGP1 might act as a new predictor of prognosis 
in ESCC patients.
In summary, the expression levels and prognostic value 
of AZGP1 in ESCC were investigated in this study for the 
first time. The results of this study demonstrated that AZGP1 
downregulation in ESCC tissues indicated aggressive tumor 
behaviors and predicted a worse clinical outcome. These 
suggested that AZGP1 might serve as a candidate tumor 
suppressor and prognostic marker in ESCC, as well as a 
potential therapeutic target for ESCC patients.
Acknowledgments
This work was supported by grants from the Key Science and 
Technology Research Foundation of Henan Province (nos 
152102410087 to Hong Tang), Ph.D. Research Foundation 
of Henan Cancer Hospital (nos 201511004 to Yufeng Wu), 
the National Science Foundation of China (nos 81272600 
to Qiming Wang).
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
14
5 
on
 0
4-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
92
Tang et al
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, 
mortality, and prevalence across five continents: defining priorities to 
reduce cancer disparities in different geographic regions of the world. 
J Clin Oncol. 2006;24(14):2137–2150.
 2. Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin 
North America. 2012;92(5):1077–1087.
 3. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. 
Esophageal cancer: an update. Int J Surg. 2010;8(6):417–422.
 4. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: 
orient to Occident. Effects of chronology, geography and ethnicity. 
J Gastroenterol Hepatol. 2009;24(5):729–735.
 5. Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resect-
able esophageal adenocarcinoma: single institution experience with 263 
patients. J Am Coll Surg. 2006;202(4):588–596; discussion 596–588.
 6. Li XH, Wang XP, Gu WS, et al. Clinical significance of preoperative 
thrombin time in patients with esophageal squamous cell carcinoma 
following surgical resection. PLoS One. 2015;10(10):e0140323.
 7. Chao YK, Chang CB, Chuang WY, et al. Correlation between tumor 
regression grade and clinicopathological parameters in patients with 
squamous cell carcinoma of the esophagus who received neoadjuvant 
chemoradiotherapy. Medicine (Baltimore). 2015;94(34):e1407.
 8. Guo JC, Huang TC, Lin CC, et al. Postchemoradiotherapy pathologic 
stage classified by the American Joint Committee on the cancer staging 
system predicts prognosis of patients with locally advanced esophageal 
squamous cell carcinoma. J Thorac Oncol. 2015;10(10):1481–1489.
 9. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and associa-
tion of beta-catenin, p16 and c-myc in multistage colorectal tumorigen-
esis and progression detected by tissue microarray. Int J Cancer. 2003; 
107(6):896–902.
 10. American Joint Committee on Cancer. AJCC Guidelines, 7th Edition; 
2009. Available from: www.cancerstaging.org.
 11. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in 
human breast cancer. An immunohistochemical study. Cancer. 1993; 
72(10):2979–2985.
 12. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Zinc alpha 
2-glycoprotein: a multidisciplinary protein. Mol Cancer Res. 2008;6(6): 
892–906.
 13. Irmak S, Tilki D, Heukeshoven J, et al. Stage-dependent increase of 
orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. 
Proteomics. 2005;5(16):4296–4304.
 14. Abdul-Rahman PS, Lim BK, Hashim OH. Expression of high-abun-
dance proteins in sera of patients with endometrial and cervical cancers: 
analysis using 2-DE with silver staining and lectin detection methods. 
Electrophoresis. 2007;28(12):1989–1996.
 15. Lei G, Arany I, Selvanayagam P, et al. Detection and cloning of epider-
mal zinc-alpha 2-glycoprotein cDNA and expression in normal human 
skin and in tumors. J Cell Biochem. 1997;67(2):216–222.
 16. Burgi W, Schmid K. Preparation and properties of Zn-alpha 2-glyco-
protein of normal human plasma. J Biol Chem. 1961;236:1066–1074.
 17. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. 
Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed 
and secreted by human (SGBS) adipocytes. FEBS Lett. 2005;579(1): 
41–47.
 18. Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipol-
ysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. 
Biochim Biophys Acta. 2004;1636(1):59–68.
 19. Bing C, Bao Y, Jenkins J, et al. Zinc-alpha2-glycoprotein, a lipid 
mobilizing factor, is expressed in adipocytes and is up-regulated in 
mice with cancer cachexia. Proc Natl Acad Sci U S A. 2004;101(8): 
2500–2505.
 20. Brysk MM, Lei G, Adler-Storthz K, et al. Zinc-alpha2-glycoprotein 
expression as a marker of differentiation in human oral tumors. Cancer 
Lett. 1999;137(1):117–120.
 21. Kong B, Michalski CW, Hong X, et al. AZGP1 is a tumor suppressor in 
pancreatic cancer inducing mesenchymal-to-epithelial transdifferentia-
tion by inhibiting TGF-beta-mediated ERK signaling. Oncogene. 2010; 
29(37):5146–5158.
 22. Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-
Otin C. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and 
correlation with clinical, histological and biochemical parameters. 
Eur J Cancer. 1993;29A(9):1256–1260.
 23. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. 
Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithe-
lium and may serve as a potential serum marker for prostate cancer. 
Clin Cancer Res. 2001;7(4):846–853.
 24. Huang CY, Zhao JJ, Lv L, et al. Decreased expression of AZGP1 is 
associated with poor prognosis in primary gastric cancer. PLoS One. 
2013;8(7):e69155.
 25. He N, Brysk H, Tyring SK, Ohkubo I, Brysk MM. Zinc-alpha(2)-
glycoprotein hinders cell proliferation and reduces cdc2 expression. 
J Cell Biochem Suppl. 2001;(Suppl 36):162–169.
 26. Descazeaud A, de la Taille A, Allory Y, et al. Characterization of 
ZAG protein expression in prostate cancer using a semi-automated 
microscope system. Prostate. 2006;66(10):1037–1043.
 27. Lapointe J, Malhotra S, Higgins JP, et al. hCAP-D3 expression marks a 
prostate cancer subtype with favorable clinical behavior and androgen 
signaling signature. Am J Surg Pathol. 2008;32(2):205–209.
 28. Huang Y, Li LZ, Zhang CZ, et al. Decreased expression of zinc-
alpha2-glycoprotein in hepatocellular carcinoma associates with poor 
prognosis. J Transl Med. 2012;10:106.
 29. Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene 
classifier specific for stage II colorectal cancer prognosis. Gut. 2012; 
61(11):1560–1567.
 30. Ji D, Li M, Zhan T, et al. Prognostic role of serum AZGP1, PEDF and 
PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6): 
1265–1272.
 31. Albertus DL, Seder CW, Chen G, et al. AZGP1 autoantibody predicts 
survival and histone deacetylase inhibitors increase expression in lung 
adenocarcinoma. J Thorac Oncol. 2008;3(11):1236–1244.
 32. Jung WY, Sung CO, Han SH, et al. AZGP-1 immunohistochemical 
marker in prostate cancer: potential predictive marker of biochemical 
recurrence in post radical prostatectomy specimens. Appl Immunohis-
tochem Mol Morphol. 2014;22(9):652–657.
 33. Bundred NJ, Walker RA, Everington D, White GK, Stewart HJ, 
Miller WR. Is apocrine differentiation in breast carcinoma of prognostic 
significance? Br J Cancer. 1990;62(1):113–117.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
14
5 
on
 0
4-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
93
aZgP1 expression in esophageal cancer
Supplementary materials
Figure S1 The relative quantify of aZgP1 mrna expression of tumor (T) was frequently downregulated in esophageal squamous cell carcinomas in comparison with their 
paired nontumor (n) tissues by rT-Pcr.
Note: β-actin was used as an internal control.
Abbreviation: rT-Pcr, real-time polymerase chain reaction.
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Figure S2 The relative quantify of aZgP1 protein expression of tumor (T) was frequently downregulated in esophageal squamous cell carcinomas in comparison with their 
paired nontumor (n) tissues by Western blot.
Notes: β-actin was used as an internal control. The arrow is showing aZgP1.
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Figure S3 The hematoxylin and eosin staining of two esophageal squamous cell carcinoma patients.
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